HIV Infections Clinical Trial
Official title:
South African Adolescent Health Promotion Project
This study will evaluate the effect of an HIV/STD risk-reduction program on the sexual behavior of South African adolescents.
HIV is a virus that can lead to acquired immunodeficiency syndrome (AIDS), a disease that
breaks down the immune system and allows for entry of life-threatening secondary infections.
HIV is transmitted through the exchange of bodily fluids, primarily through sexual
intercourse. South Africa has been one of the countries in which the AIDS pandemic has had
an especially devastating effect. New cases of HIV infection in South Africa have been
occurring at a high rate in people 15 to 24 years of age. There is no vaccine or cure for
HIV yet, making disease prevention methods imperative. An important part of the prevention
process is early education on HIV to reduce sexual-risk behavior and to promote safe sexual
practices. This study will evaluate the effect of an HIV/STD risk-reduction program on the
sexual behavior of South African adolescents.
In this single-blind study, participants will include sixth grade students from 18 South
African schools that meet study criteria. The participants will be randomly divided into 2
structurally similar treatment groups. One group will take part in HIV/STD risk-reduction
sessions, while the other group will take part in health promotion sessions. There will be
12 total sessions, each lasting 1 hour. The participants in the HIV/STD risk-reduction group
will be taught to practice abstinence and condom use through interactive activities, comic
workbooks, and take-home assignments. Through similar methods, the participants in the
health promotion group will be taught about general health problems, such as heart disease,
diabetes, alcohol and drug abuse, and certain cancers. Participants will also be taught
healthful behaviors to help prevent these health problems. All participants will provide
self-reports of sexual behavior and precautionary methods used in sexual intercourse
immediately before the first and after the last treatment sessions. Follow-up evaluations
will occur at Months 3, 6, 12, 42, and 54 months post-treatment. STDs will be assessed 42
and 54 months post-treatment
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |